NEW YORK, Feb. 14 (GenomeWeb News) - Gen-Probe is funding a three-year study at the Center for Prostate Disease Research aimed at developing a new diagnostic test for prostate cancer, according to the Henry M. Jackson Foundation, which manages CPDR programs.
Under the deal, Gen-Probe will get a non-exclusive license to develop and commercialize the resulting test, the foundation said in a statement released today.
Financial details were not provided.
CPDR is currently trying to asses the clinical utility of expression alterations of a novel prostate-specific gene, PCGEM1, and the ETS-related gene, ERG, in prostate patients.
"The primary goal of the initiative is to create a new generation of highly specific gene panels in urine. ... This work could complement or significantly improve the currest PSA blood test, which suffers from lack of specificity," said CPDR co-director Shiv Srivastava, who will lead the studies with Harry Rittenhouse, Gen-Probe senior director of cancer research.
Under the agreement, CPDR's oncogenes may be studied in combination with other prostate cancer markers owned by Gen-Probe, including PCA3 and AMACR.
The CPDR was established in 1991 through collaboration between the Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation. The USU-HJF have jointly filed several patent applications on the unique use of the combined panel of genes as well as on new genes discovered by CPDR.